Thyrotoxicosis is a known risk factor for osteoporosis. Patients with thyrotoxicosis have reduced bone mineral density (BMD) (1) (2) (3) . As a result, individuals with a history of thyrotoxicosis have an increased risk of hip fracture (4) and appear to sustain fractures at an earlier age than individuals who have never been thyrotoxic (5) . Early treatment of thyrotoxicosis can prevent bone loss in subclinical hyperthyroidism (6) , whereas ade¬ quate therapy in overt hyperthyroidism can only partially restore bone mass, thus possibly reducing fracture risk (7) . Thus, thyrotoxicosis reduces bone mass and appears to increase the risk of subsequent fracture. Because the bone loss due to thyrotoxicosis appears to be at least partially reversible, early detection would be expected to at least partially restore bone mass and minimize fracture risk.
In an attempt to define the molecular effects of thyroid hormone on the skeleton, we have employed a rodent model given supraphysiological doses of lthyroxine (l-T4). We have reported previously that short-term (3 weeks) treatment with l-T4 decreased femoral, but not vertebral, BMD in young (8-week) male rats (8) . The (Table 1 ). There were no statistically significant differences in lumbar vertebral BMD between the l-T4 and control groups throughout the course of the study (Table 1 ).
More total cellular RNA per gram of tissue was isolated from the femurs than from vertebrae in both the l-T4 and control animals ( Table 3 ). The amount of total RNA per gram of tissue isolated from the femurs of the l-T4 group was significantly greater than that from the control group (2.70 ± 0.10 vs 2.27 ± 0.07; < 0.01). L-Thyroxine did not increase total RNA in the vertebrae but significantly increased mRNA levels of osteocalcin, osteopontin, alkaline phosphatase and TRAP by 94%, 116%, 180% and 89%, respectively, in femoral bone (p< 0.001) (Table 4 and Fig. 2 ). There was no significant difference in these gene expression markers between l-T4 and control animals in vertebral bone (Table 4 and Fig. 2 ).
Discussion
We have shown that prolonged treatment (20 (22) . Osteoblasts respond to triiodothyronine with an increase in the production of osteocalcin (17) , alkaline phosphatase (20) and insulin¬ like growth factor I (23) . This direct effect of thyroid hormone on the osteoblasts most likely accounts for the increased circulating levels of alkaline phosphatase (24) and osteocalcin (25, 26) (27) . The duration of therapy in this study (20 weeks) should have been adequate to elicit a response in the vertebral osteoblasts. A similar study administering l-T4 to 1-year-old rats showed no effect on vertebral or femoral ash weight or femoral strength (28) . The (29, 30) . A better under¬ standing of this site specificity of thyroid hormone action should facilitate therapy designed to prevent bone loss in patients requiring TSH-suppressive doses of l-T4.
